Searchable abstracts of presentations at key conferences in endocrinology

ea0005p131 | Endocrine Tumours and Neoplasia | BES2003

The presence of ghrelin protein in the rat hypothalamus and the effect of ghrelin on corticotrophin releasing hormone (CRH) and arginine vasopressin (AVP) release from rat hypothalamic explants pituitary tumours

Mozid A , Tringali G , Forsling M , Hendricks M , Ajodha S , Edwards R , Navarra P , Grossman A , Korbonits M

Ghrelin is a brain-gut peptide originally identified in the stomach. It binds to and stimulates the growth hormone secretagogue receptor type 1a (GHS-R). The presence of ghrelin in hypothalamic tissue was studied. It has been previously established that neither the synthetic GHSs, nor the endogenous hormone ghrelin, is specific for GH stimulation: they generally also stimulate the HPA axis as well as prolactin release. Since there is no direct stimulatory effect on ACTH releas...

ea0005p185 | Neuroendocrinology and Behaviour | BES2003

Abnormal endocrine tests in chronic pain require investigation and are not the result of opioid analgesia

Merza Z , Edwards N , Walters S , Newell-Price J , Ross R

Background: Anecdotally patients with chronic pain on opioid analgesia have functional hypopituitarism, and studies in opioid addicts show suppressed pituitary function. We conducted a prospective observational study to determine the endocrine status of patients with chronic pain on opioid analgesia. Methods: 37 consecutive patients with chronic back pain attending the pain clinic were enrolled. 22 patients (age 45+/-9 years) were on long-term opioid analgesia and 15 (age 53 +...

ea0063gp250 | Disturbances of Reproduction | ECE2019

Diagnostic potential of a ‘mouse azoospermia’ gene panel in human azoospermia: identification of novel genetic causes of meiotic arrest

Riera-Escamilla Antoni , Enguita-Marruedo Andrea , Moreno-Mendoza Daniel , Chianese Chiara , Ruiz-Castane Eduard , Maggi Mario , Baarends Willy , Krausz Csilla

Purpose: Non-Obstructive Azoospermia (NOA), occurring in approximately 1% of men, has an unknown etiology in the majority of cases. This study aims at evaluating the diagnostic efficiency of a gene panel contemplating all known genes associated with azoospermia in mice.Subjects and methods: Design of a ‘mouse azoospermia’ gene panel through the consultation of MGI; selection of 175 mouse azoospermia genes with human orthologues; selection of 31...

ea0056oc2.3 | Look who is controlling your gonads! | ECE2018

Whole exome sequencing in non-obstructive azoospermia allows the identification of a high-risk subgroup of infertile men for undiagnosed Fanconi Anemia, a cancer-prone disease

Krausz Csilla , Riera-Escamilla Antoni , Chianese Chiara , Moreno-Mendoza Daniel , Rajmil Osvaldo , Ruiz-Castane Eduard , Surralles Jordi

Background: The etiology of non-obstructive azoospermia (NOA) remains unknown in about 40% of cases and genetic factors are likely to be involved in a large proportion of them. Gene mutations involved in stem cell proliferation and DNA repair may cause isolated NOA or be responsible for syndromic diseases, such as Fanconi Anemia (FA). Although the most frequent presenting symptom in FA is bone marrow failure in childhood, in about 10% of cases the diagnosis is delayed until ad...

ea0042p9 | (1) | Androgens2016

The deubiquitinating enzyme USP12 controls prostate cancer cell survival by regulating the AR-AKT-p53 signalling network

McClurg Urszula L , Chit Nay C T H , Nakjang Sirintra , Edwards Joanne , McCracken Stuart R , Robson Craig N

We previously demonstrated that USP12 functions as an AR co-activator by directly deubiquitinating the AR and stabilising its protein levels. Additionally, we showed that USP12 targets the PHLPP AKT phosphatases leading to decreased levels of activated, phosphorylated AKT (pAKT) and as such indirectly stabilises the AR preventing its phosphorylation at serine 213. We further investigated the role of USP12 in prostate cancer by analysing the transcriptome of the LNCaP prostate ...

ea0010dp4 | Diabetes, metabolism and cardiovascular | SFE2005

Familial diabetes in Asian families; remember MODY

Porter J , Rangasami J , Ellard S , Gloyn A , Edwards J , Anderson J , Plunkett M , Shaw N , Frayling T , Hattersley A , Barrett T

Type 2 diabetes (T2DM) has emerged in youth, disproportionately affecting ethnic minorities. Maturity Onset Diabetes of the Young (MODY) has been reported in exclusively white UK children. We report the first UK Asian children with MODY, highlighting differences from T2DM.Child 1 is a slim (BMI SDS−0.14) female of Indian descent without acanthosis nigricans (AN). She presented aged 12 years with polydipsia and polyuria (HbA1c 8.6%). Hypoglycaemia w...

ea0009p137 | Steroids | BES2005

Development of a cortisol binding capacity assay for use in the newborn

Smith J , Armstrong L , Hoftijzer D , Midgley P , Mallam B , Armstrong J , Yorke J , Edwards A , Wilson C

Background: The action of a steroid in any physiological process is dependent on the bioavailable (free) fraction. Direct measurements of free cortisol are expensive, labour intensive and require a significant volume of plasma and as a consequence are not feasible in the neonate. One alternative is to calculate free cortisol from the Cortisol Binding Capacity (CBC) and the total plasma cortisol. The aim of the present study was to develop an assay for the measurement of CBC in...

ea0045oc9.1 | Oral Communications 9- Nurses | BSPED2016

A review of junior doctors’ knowledge of the management of newborn disorders of sexual development

Alsaffar Hussain , Turner Lucy , Odedun Rebecca , Giri Dinesh , Edwards Zoe , Blair Jo , Kenny Simon , Senniappan Senthil , McAndrew Fiona , Das Urmi

Introduction: Disorders of sexual development (DSDs) are estimated to occur in 1 in 4500 births. This potentially represents one baby born every other day in the UK. We aim to explore how Mersey foundation and paediatric trainees deal with newborn babies with possible DSD and identify if there is a need for further training in this subject.Methods: An online survey composed of 10 questions was distributed amongst foundation and paediatric trainees in Mer...

ea0095oc1.2 | Oral Communications 1 | BSPED2023

45,X/46,XY DSD with gender dysphoria: the conundrum around pubertal induction

Chatterjee Sumana , Alderson Julie , Edwards Zoe , Mcandrew Fiona , Williams Cara , Das Urmi , Awad Karim , Park Julie , Giri Dinesh

Introduction: Mixed gonadal dysgenesis (MGD) is a rare form of difference in sex development (DSD) characterised by mosaic karyotype of 45,X/46,XY and dysgenetic gonads. Gender dysphoria can be associated, the frequency of which is unknown. We describe 2 cases of MGD with gender dysphoria and the conundrum around pubertal induction.Case 1: An 8-year-old, reared as a girl, presented with longstanding concerns about appear...

ea0086p194 | Endocrine Cancer and Late Effects | SFEBES2022

The incidence and clinical significance of metabolically active brown adipose tissue in patients with pheochromocytomas and paragangliomas: A retrospective cohort study, systematic review and meta-analysis

Onyema Michael , Ostarijas Eduard , Minhas Raisa , Roy Aparajita , Kearney Jessica , Omran Asma , Zair Zoulikha , Reynolds Saira , Mulholland Nicola , Corcoran Benjamin , Halim Mohammad , Aylwin Simon , Dimitriadis Georgios K

There is limited research into the impact of active brown adipose tissue (aBAT) in patients with phaeochromocytomas and paragangliomas (PPGLs). A small body of evidence has shown that patients with PPGL patients can exhibit a high prevalence for aBAT recognized as ranging between 8 - 28% without specific correlation to germline mutations. Furthermore, it has been suggested that aBAT may be linked to increased mortality. Systematic searches of the Medical Literature Analysis an...